Table 1.
Demographic data | N = 131 |
---|---|
Median age, (IQR) | 8 (4–14) |
Male sex, n (%) | 75 (57) |
Country, n (%) | |
|
10 (8) |
|
26 (20) |
|
5 (4) |
|
2 (1.5) |
|
2 (1.5) |
|
41 (31) |
|
21 (16) |
|
12 (9) |
|
9 (7) |
|
3 (2) |
Underlying diagnosis, n (%) | |
|
60 (46) |
|
18 (14) |
|
48 (37) |
|
5 (4) |
Active cancer treatment, n (%) | 100 (76) |
|
31a |
GVHD, n (%) | |
|
2 (2) |
|
2 (2) |
|
1 (0.8) |
CAR-T treatment, n (%) | 3 (2) |
No comorbidity, n (%) | 96 (73) |
At least one comorbidity | 35 (27) |
|
8 |
|
7 |
|
5 |
|
4 |
|
4 |
|
2 |
|
2 |
|
2 |
|
7 |
Bacterial coinfection (n = 5) | |
|
4 |
|
1 |
|
1 |
|
1 |
Viral coinfection (n = 5) | |
|
2 |
|
1 |
|
1 |
|
1 |
Invasive fungal infection (n = 3) | |
|
1 |
|
1 |
|
1 |
Median neutrophil count, cells/mm3 (IQR) | 805 (155–2020) |
Median lymphocyte count, cells/mm3 (IQR) | 530 (190–1030) |
IQR, interquartile range; GVHD, graft versus host disease; BMI, body mass index.
Unknown in n = 43.
Includes children with brain tumour affecting the pituitary stalk (n = 4) or long-term immunosuppression (n = 3).
All patients in whom the tumour has caused brain damage.
Includes patients with Down syndrome, psoriasis, xeroderma pigmentosum, Niemann-Pick disease, kidney transplantation, Kaposi sarcoma and Russel's syndrome.